AstraZeneca's (AZN.US) Phase III study for chronic sinusitis with nasal polyps met its primary endpoint

AstraZeneca (AZN.US) announced that the Phase III WAYPOINT study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) met its co-primary endpoints. The results showed a statistically significant and clinically meaningful reduction in nasal polyp size and improvement in nasal congestion symptoms in the Tezepelumab treatment group.

Public information shows that Tezepelumab is a first-in-class monoclonal antibody co-developed by AstraZeneca and Amgen, which inhibits thymic stromal lymphopoietin (TSLP). TSLP is a key epithelial cytokine located upstream of multiple inflammatory cascades and is associated with diseases such as asthma, CRSwNP, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE). Tezspire blocks TSLP, thereby preventing immune cells from releasing pro-inflammatory cytokines, achieving therapeutic effects for related diseases.

It is known that Tezepelumab has been approved in the US for the treatment of severe asthma, and its Phase III clinical study is ongoing in China. In addition to CRSwNP, Tezepelumab is being developed for other potential indications, including COPD and EoE.